Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-408-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.02 million
Profitability
Miscellaneous
Employees138
OptionableOptionable
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) posted its quarterly earnings data on Friday, November, 9th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.03. The business earned $12.50 million during the quarter, compared to analyst estimates of $14.80 million. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
4 analysts have issued 1 year price targets for Neos Therapeutics' stock. Their forecasts range from $6.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 491.1% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.
What is the consensus analysts' recommendation for Neos Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (1/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys XR-ODT, Cotempla XR- ODT and Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0501) will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher." (11/9/2018)
Has Neos Therapeutics been receiving favorable news coverage?
News headlines about NEOS stock have trended very positive on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neos Therapeutics earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Axsome Therapeutics (AXSM), AVEO Pharmaceuticals (AVEO), Acer Therapeutics (ACER), resTORbio (TORC), Aldeyra Therapeutics (ALDX), Seres Therapeutics (MCRB), Dova Pharmaceuticals (DOVA), Magenta Therapeutics (MGTA), TAIWAN LIPOSOME/S (TLC), Syros Pharmaceuticals (SYRS), Strongbridge Biopharma (SBBP), MannKind (MNKD), CELYAD SA/ADR (CYAD), Avid Bioservices (CDMO) and Affimed (AFMD).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 61)
- Mr. Gerald W. McLaughlin, CEO & Director (Age 51)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 47)
- Mr. Darren Heath, VP of Sales
- Mr. Russ McMahen, Sr. VP of R&D
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $2.03.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $60.24 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
What is Neos Therapeutics' official website?
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
